HM2026-05: A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment)

Project: Research project

Status	Active
Effective start/end date	2/25/26 → 2/24/36

Project Details